Enterome's EO2463 Receives FDA Orphan Drug Designation for Indolent Non-Hodgkin Lymphoma Treatment
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimicsTM to treat "watch-and-wait" indolent non-Hodgkin lymphoma
Image: Benzinga
Enterome SA has received Orphan Drug Designation from the U.S. FDA for EO2463, aimed at treating indolent non-Hodgkin lymphoma (iNHL) patients in the 'watch-and-wait' phase. This designation provides significant regulatory and financial benefits, highlighting the need for effective treatments in this patient population.
- 01EO2463 has demonstrated a 52.6% objective response rate in patients with follicular lymphoma during clinical trials.
- 02The drug's Orphan Drug Designation provides 7 years of market exclusivity upon approval in the U.S.
- 03EO2463 showed a 60% complete response rate when combined with lenalidomide and rituximab in patients with relapsed/refractory lymphoma.
- 04The ongoing SIDNEY trial is evaluating EO2463's safety and efficacy in various lymphoma settings, including a dedicated watch-and-wait cohort.
- 05Enterome is actively seeking partnerships and investments to expedite EO2463's development for iNHL patients.
Advertisement
In-Article Ad
Enterome SA, a clinical-stage biopharmaceutical company based in Paris, has announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for EO2463, a treatment for patients with indolent non-Hodgkin lymphoma (iNHL) in the 'watch-and-wait' setting. This designation provides Enterome with crucial regulatory and financial advantages, including 7 years of market exclusivity upon approval. EO2463 has shown promising results in clinical trials, achieving a 52.6% objective response rate in patients with follicular lymphoma. The drug is designed to stimulate the immune response against malignant B cells, making it a potential game-changer for patients who currently have no treatment options. Additionally, EO2463 demonstrated a 60% complete response rate when used in combination with lenalidomide and rituximab for relapsed/refractory cases. The ongoing SIDNEY study aims to further assess the drug's safety and efficacy across different lymphoma stages, including a specific cohort for watch-and-wait patients. Enterome is also in discussions with potential partners to accelerate EO2463's development.
Advertisement
In-Article Ad
The approval of EO2463 could provide a viable treatment option for patients with indolent non-Hodgkin lymphoma who currently face a watch-and-wait approach, potentially improving their quality of life and reducing anxiety.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of EO2463 for treating indolent non-Hodgkin lymphoma?
Connecting to poll...
Read the original article
Visit the source for the complete story.